文献速递心律失常心力衰竭与心肌病

心肌病相关致病基因变异与房颤患者预后:18,000例临床试验参与者结果

Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.
PubMed 文献 · J Am Coll Cardiol · 2025-01-01

在5项跨国临床试验的17,190例房颤患者中,2.4%携带心肌病相关致病基因变异,该类变异与心衰病史、心衰住院及心血管死亡风险升高相关,但与缺血性卒中无关,EAST-AFNET-4试验重复验证了心衰相关关联。

要点

  • 房颤患者中2.4%携带心肌病相关致病基因变异,与心衰病史及心衰住院风险升高相关。
  • 该类变异与心血管死亡风险呈名义关联,主要由扩张型心肌病相关变异驱动。
  • 该类变异与缺血性卒中无关,尽管抗凝使用率较高。

核心结论

  • 在房颤患者中,罕见心肌病基因变异与心衰住院和心血管死亡风险升高相关,但与卒中无关。

研究设计与样本

  • 利用TIMI研究组5项跨国临床试验(ENGAGE AF、FOURIER、SAVOR、PEGASUS、DECLARE)的外显子测序数据,并在EAST-AFNET-4试验中重复验证。
  • 在17,190例有房颤病史的患者中识别CMP-PLP携带者,采用逻辑回归和Cox回归分析中心 adjudicated 结局。

主要发现

  • 在17,190例房颤患者中,识别出421例(2.4%)CMP-PLP携带者。
  • CMP-PLP变异与心衰病史相关(OR: 1.66; P < 0.0001),以扩张型心肌病相关变异最显著。
  • CMP-PLP变异与心衰住院相关(HR: 1.75; 95% CI: 1.34-2.29; P < 0.0001),以肥厚型心肌病和致心律失常性右心室心肌病变异最显著。
  • CMP-PLP变异与心血管死亡呈名义关联(HR: 1.46; 95% CI: 1.06-2.02; P = 0.02),主要由扩张型心肌病相关变异驱动。
  • CMP-PLP变异与现患(OR: 0.99; P = 0.96)或新发(HR: 0.95; P = 0.84)缺血性卒中无关,尽管抗凝使用率高。

临床怎么用

  • 对房颤患者进行心肌病相关基因变异评估可能有助于识别心衰住院和心血管死亡高风险个体。
  • 携带CMP-PLP变异的房颤患者应加强心衰监测与管理,但卒中风险未见升高。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), although data on clinical outcomes for AF patients with such variants remain sparse. OBJECTIVES: We aimed to study the prognostic implication of rare cardiomyopathy-associated pathogenic variants (CMP-PLP) in AF patients from large, well-phenotyped clinical trials. METHODS: CMP-PLP carriers were identified using exome sequencing in 5 multinational trials from the Thrombolysis in Myocardial Infarction study group (ENGAGE AF, FOURIER, SAVOR, PEGASUS, and DECLARE), with replication in the EAST-AFNET-4 trial. Associations with centrally adjudicated outcomes were assessed using logistic and Cox regression, among patients with AF. RESULTS: In 17,190 patients with a history of AF, we identified 421 (2.4%) CMP-PLP carriers. CMP-PLP variants were associated with a history of heart failure (HF) (OR: 1.66; P < 0.0001), most notably for dilated cardiomyopathy-associated variants. CMP-PLP variants were also associated with incident HF hospitalizations (HR: 1.75; 95% CI: 1.34-2.29; P < 0.0001), most notably for hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy variants. CMP-PLP variants were nominally associated with increased risk of cardiovascular death (HR: 1.46; 95% CI: 1.06-2.02; P = 0.02), driven mainly by dilated cardiomyopathy-associated variants. In contrast, CMP-PLP variants were not associated with prevalent (OR: 0.99; P = 0.96) or incident (HR: 0.95; P = 0.84) ischemic stroke, although anticoagulation use was high. In replication, among 1,479 EAST-AFNET-4 participants, CMP-PLP variants were also associated with prevalent HF and incident HF hospitalizations. CONCLUSIONS: In patients with AF, rare cardiomyopathy gene variants are associated with increased risks of HF hospitalizations and cardiovascular death, but not stroke. These results, collected from large well-phenotyped clinical trials, demonstrate important prognostic implications for cardiomyopathy-associated genetic variants in AF patients.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Jurgens, Melloni, Kany, et al. Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants. J Am Coll Cardiol. 2025. PMID: 40903137. doi:10.1016/j.jacc.2025.06.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。